|
Profit before tax increased 35.93% to Rs 275.94 crore in Q2 FY24 as compared with Rs 203 crore in Q2 FY23.
EBITDA stood at Rs 291 crore in Q2 FY24, up 48% as against Rs 196 crore posted in corresponding quarter last year. EBITDA margin was at 28% during the quarter.
During the quarter, total branded generic sales was up 4% to Rs 743 crore as compared with Rs 711 crore posted in Q2 FY23.
In quarter ended 30 september 2023, revenue from India stood at Rs 355 crore (up 13% YoY ), revenue from Africa stood at Rs 157 crore (up 8% YoY), revenue from US stood at Rs 237 crore (up 28% YoY) while revenue from Asia was at Rs 230 crore (down 8% YoY).
During Q2 FY24, R&D expenses were Rs 50 crore, which is 5% of revenue from operations. R&D expenses were Rs 59 crore in Q2 FY23.
Ajanta Pharma is a specialty pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa.
The shares of Ajanta Pharma were higher 0.48% to Rs 1,763.95 on the BSE.
|